Consistent with this, targeting LSD1 through short hairpin RNA–mediated knockdown or through more potent analogs of TCP induced differentiation as well as loss of clonogenic potential of murine and human MLL leukemia cells both ex vivo and in vivo (37). The gene discussed is KMT2A; the disease is leukemia.